Published: 2016-09-28

The role of inflammation in cardiac arrhythmias pathophysiology

Wielospecjalistyczny Szpital SP ZOZ w Nowej Soli
Katedra i Zakład Patofizjologii Uniwersytetu Medycznego w Poznaniu
Katedra i Zakład Patofizjologii Uniwersytetu Medycznego w Poznaniu
inflammation atrial fibrillation biomarkers remodeling


The pathophysiology of cardiac arrhythmias is highly complex. Inflammation causes electrophysiological changes that contribute to increased vulnerability of arrhythmias, a process known as electrical remodeling. There have been many biomarkers and proteins associated with pathophysiology of cardiac arrhythmias such as C-reactive protein, tumor necrosis factor-?, interleukin-2, interleukin-6, interleukin-8, and monocyte chemoattractant protein-1. At present large attention is paid to the clinical studies on the inflammation in the pathogenesis of the atrial fibrillation (AF), given the limited effectiveness of the current therapeutic approaches. Understanding the main process, molecular mechanism and signaling pathways underlying the pathogenesis of the inflammatory dilated cardiomyopathy (iDCM) will be essential for developing new effective therapeutic strategies.


Download data is not yet available.


  1. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–445.
  2. Libby P. Inflammation and cardiovascular disease mechanisms. The American journal of clinical nutrition. 2006;83(2):456–460.
  3. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. 2007;38:1229–1237.
  4. Feuerstein GZ, Libby P, Mann DL. Inflammation—a new frontier in cardiac disease and therapeutics. Inflammation and Cardiac Diseases. Birkhäuser Basel. 2003; 1–5.
  5. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nature Reviews Cardiology. 2015;12(4):230–243.
  6. Pasquie JL, Sanders P, Hocini M et al. Fever as a precipitant of idiopathic ventricular fibrillation in patients with normal hearts. J Cardiovasc Electrophysiol. 2004;15:1–6.
  7. Klein RM,Vester EG, Brehm MU et al. Inflammation of the myocardium as an arrhythmia trigger. Zeitschrift fur Kardiologie. 1999;89:24–35.
  8. Pieroni M, Smaldone C, Bellocci F. Myocarditis presenting with ventricular arrhythmias: role of electroanatomical mapping-guided endomyocardial biopsy in differential diagnosis. In Cihakova D, ed. Myocarditis. InTech Open Access Publisher. 2011:365–386.
  9. Saito, Junko, Niwano S, Niwano H et al. Electrical remodeling of the ventricular myocardium in myocarditis. Circulation Journal. 2002;66(1):97–103.
  10. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial ?brillation. Circulation. 1997;96:1180–1184.
  11. Maixent JM, Paganelli F, Scaglione J, Levy S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. Journal of cardiovascular electrophysiology. 1998;9(6):612–617.
  12. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: strategies to control, combat, and cure. Lancet. 2002;359:593–603.
  13. Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH; Impact of rate versus rhythm control on quality of life in patients with persistent atrial ?brillation: results from a prospective randomized study. Eur Heart J. 2003;24:1430–1436.
  14. Haissaguerre M, Marcus FI, Fischer B, Clementy J. Radiofrequency catheter ablation in unusual mechanisms of atrial fibrillation. J Cardiovasc Electrophysiol. 1994;5:743–751.
  15. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial ?brillation begets atrial ?brillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954–1968.
  16. Li J, Solus J, Chen Q et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010;7(4):438–444.
  17. Blake GJ, Ridker PM. C-reactive protein and other in?ammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41(Suppl. 4):37–42.
  18. Aulin J et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. American Heart Journal. 2015;170(6):1151–1160.
  19. Polovina MM, Ostojic MC, Potpara TS. Relation of biomarkers of inflammation and oxidative stress with hypertension occurrence in lone atrial fibrillation. Mediators of inflammation. 2015. Doi: 10.1155/2015/653026.
  20. Gibson PH, Cuthbertson BH, Croal BL et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. The American Journal of Cardiology. 2010;105(2):186–191.
  21. Aydin M, Yildiz A, Yüksel M et al. Assessment of the neutrophil/lymphocyte ratio in patients with supraventricular tachycardia. Anatolian journal of cardiology. 2015; 15(0):000–000
  22. Lau DH, Mackenzie L, Kelly DJ et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm. 2010;7: 1282–1290.
  23. De Jong AM, Maass AH, Oberdorf-Maass SU, Van Veldhuisen DJ, Van Gilst WH, Van Gelder IC, et al. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res. 2011;89:754–765.
  24. Boos CJ, Anderson RA, Lip GY. Novel therapies for the prevention of stroke. Expert Opin Investig Drugs, 2004;13:1615–1630.
  25. Bruins P, te Velthuis H, Yazdanbakhsh AP et al. Activation of the complement system during and after cardiopulmonary bypass surgery postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96(10):3542–3548.
  26. Ishida K, Kimura F, Imamaki M et al. Relation of inflammatory cytokines to atrial fibrillation after off-pump coronary artery bypass grafting. European Journal of Cardio-Thoracic Surgery. 2006;29(4):501–505.
  27. Marcus GM, Smith LM, Glidden DV et al. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm. 2008;5(2):215–221.
  28. Richter B, Gwechenberger M, SocasA, et al. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clinical Research in Cardiology. 2012;101(3):217–225.
  29. Lim HS, Schultz C, Dang J et al. Time course of inflammation, myocardial injury, and prothrombotic response after radiofrequency catheter ablation for atrial fibrillation. Circulation: Arrhythmia and Electrophysiology. 2014;7(1):83–89.
  30. Oswald H, Gardiwal A, Lissel C et al. Difference in humoral biomarkers for myocardial injury and inflammation in radiofrequency ablation versus cryoablation. Pacing and clinical electrophysiology. 2007;30(7):885–890
  31. Malmborg H, Christersson C, Lönnerholm S, Blomström-Lundqvist C et al. Comparison of effects on coagulation and inflammatory markers using a duty-cycled bipolar and unipolar radiofrequency pulmonary vein ablation catheter vs. a cryoballoon catheter for pulmonary vein isolation. Europace. 2013;15(6):798–804.
  32. Dobrev D, Carlsson L, Nattel S. Novel molecular targets for atrial fibrillation therapy. Nature Reviews Drug Discovery. 2012;11(4):275–291.
  33. Lee SH, Chen YC, Chen YJ et al. Tumor necrosis factor-? alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci. 2007;80:1806–1815.
  34. Kao YH, Chen YC, Cheng CC et al. Tumor necrosis factor-? decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit. Care Med. 2010;38:217–222
  35. Liao CH, Akazawa H, Tamagawa M et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest. 2010;120:242–253.
  36. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. The American journal of cardiology. 2005;95(6):764–767
  37. Li SB, Yang F, Jing L et al. Myeloperoxidase and risk of recurrence of atrial fibrillation after catheter ablation. J Investig Med. 2013;61:722–727.
  38. Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2015: euv319.
  39. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105:2595–2599.
  40. Sajadieh A, Nielsen OW, Rasmussen V, Ole Hein H, Hansen JF. Increased ventricular ectopic activity in relation to C-reactive protein, and NT-pro-brain natriuretic peptide in subjects with no apparent heart disease. Pacing Clin Electrophysiol. 2006;29:1188–1194.
  41. Sagar S, Liu PP, Cooper LT. Myocarditis. The Lancet. 2012;379(9817):738–747.
  42. Baksi, AJ, Kanaganayagam GS, Prasad SK. Arrhythmias in Viral Myocarditis and Pericarditis. Cardiac electrophysiology clinics. 2015;7(2):269–281.
  43. JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version. Circulation journal: official journal of the Japanese Circulation Society. 2011;75(3):734.
  44. Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant myocarditis in Japan. Circulation Journal. 2002;66(2):133–144.
  45. Nakashima H, Umeyama Y, Minami K. Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support. Medical Science Monitor Basic Research. 2013;14:116–119.
  46. Bironaite D, Daunoravicius D, Bogomolovas J, et al. Molecular mechanisms behind progressing chronic inflammatory dilated cardiomyopathy. BMC cardiovascular disorders. 2015;15(1):1.
  47. Kawai Ch. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death learning from the past for the future. Circulation. 1999;99(8):1091–1100.
  48. Imazio M, Brucato A, Barbieri A et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter prospective cohort study. Circulation (2013): CIRCULATIONAHA-113.
  49. Imazio M, Brucato A, Maestroni S et al. Prevalence of C-Reactive Protein Elevation and Time Course of Normalization in Acute Pericarditis Implications for the Diagnosis, Therapy, and Prognosis of Pericarditis. Circulation. 2011;123(10):1092–1097.
  50. Feng D, Glockner J, Kim K et al. Cardiac Magnetic Resonance Imaging Pericardial Late Gadolinium Enhancement and Elevated Inflammatory Markers Can Predict the Reversibility of Constrictive Pericarditis After Antiinflammatory Medical Therapy A Pilot Study. Circulation. 2011;124(17):1830–1837.

How to Cite

Budzianowski JK, Korybalska K, Bręborowicz A. The role of inflammation in cardiac arrhythmias pathophysiology. JMS [Internet]. 2016Sep.28 [cited 2020Aug.9];85(3):197-204. Available from: